The primary aim of this study was to collect national epidemiological data on candidaemia and to determine the reporting time of species identification and antifungal susceptibility in clinical practice. During a 1-year period (March 2013 until February 2014), every first Candida isolate from each episode of candidaemia was included prospectively from 30 Belgian hospitals. Identification and susceptibility testing were performed according to local procedures and isolates were sent to the National Reference Center for Mycosis. Species identification was checked by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) and internal transcribed spacer (ITS) sequencing in case no reliable identification was obtained by MALDI-TOF MS. Antifungal susceptibility testing was performed according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) methodology. A total of 355 isolates were retrieved from 338 patients. The mean incidence rate of candidaemia was 0.44 (range: 0.07 to 1.43) per 1000 admissions or 0.65 (range: 0.11 to 2.00) per 10,000 patient days. Candida albicans was most frequently found (50.4 %), followed by C. glabrata (27.3 %) and C. parapsilosis sensu lato (9.8 %). The overall resistance to fluconazole was 7.6 %, ranging from 3.9 % in C. albicans to 20.0 % in C. tropicalis. Only one C. glabrata isolate was resistant to the echinocandins. Four days after blood culture positivity, 99.7 % of the identifications and 90.3 % of the antifungal profiles were reported to the treating clinician. Candidaemia incidence rates differed up to 20-fold among Belgian hospitals; no clear factors explaining this difference were identified. The overall antifungal resistance rates were low but high azole resistance rates were recorded in C. tropicalis.
Vallabhaneni Snigdha, Mody Rajal K., Walker Tiffany, Chiller Tom, The Global Burden of Fungal Diseases, 10.1016/j.idc.2015.10.004
Tortorano A. M., Peman J., Bernhardt H., Klingspor L., Kibbler C. C., Faure O., Biraghi E., Canton E., Zimmermann K., Seaton S., Grillot R., Epidemiology of Candidaemia in Europe: Results of 28-Month European Confederation of Medical Mycology (ECMM) Hospital-Based Surveillance Study, 10.1007/s10096-004-1103-y
Caggiano Giuseppina, Coretti Caterina, Bartolomeo Nicola, Lovero Grazia, De Giglio Osvalda, Montagna Maria Teresa, CandidaBloodstream Infections in Italy: Changing Epidemiology during 16 Years of Surveillance, 10.1155/2015/256580
Ericsson J., Chryssanthou E., Klingspor L., Johansson A.G., Ljungman P., Svensson E., Sjölin J., Candidaemia in Sweden: a nationwide prospective observational survey, 10.1111/1469-0691.12111
Hesstvedt L., Gaustad P., Andersen C.T., Haarr E., Hannula R., Haukland H.H., Hermansen N.-O., Larssen K.W., Mylvaganam H., Ranheim T.E., Sandven P., Nordøy I., Kanestrøm A., Grub C., Onken A., Thielsen C., Skaare D., Tofteland S., Sønsteby L.-J., Hjetland R., Hide R., Vik E., Kümmel A., Åsheim S., Twenty-two years of candidaemia surveillance: results from a Norwegian national study, 10.1016/j.cmi.2015.06.008
Nieto M.C., Tellería O., Cisterna R., Sentinel surveillance of invasive candidiasis in Spain: epidemiology and antifungal susceptibility, 10.1016/j.diagmicrobio.2014.05.021
Guinea J., Zaragoza O., Escribano P., Martin-Mazuelos E., Peman J., Sanchez-Reus F., Cuenca-Estrella M., , Molecular Identification and Antifungal Susceptibility of Yeast Isolates Causing Fungemia Collected in a Population-Based Study in Spain in 2010 and 2011, 10.1128/aac.02155-13
Orasch C., Marchetti O., Garbino J., Schrenzel J., Zimmerli S., Mühlethaler K., Pfyffer G., Ruef C., Fehr J., Zbinden R., Calandra T., Bille J., Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland, 10.1111/1469-0691.12440
Bitar Dounia, Lortholary Olivier, Le Strat Yann, Nicolau Javier, Coignard Bruno, Tattevin Pierre, Che Didier, Dromer Françoise, Population-Based Analysis of Invasive Fungal Infections, France, 2001–2010, 10.3201/eid2007.140087
Lagrou K., Verhaegen J., Peetermans W. E., Rijdt T., Maertens J., Wijngaerden E., Fungemia at a tertiary care hospital: incidence, therapy, and distribution and antifungal susceptibility of causative species, 10.1007/s10096-007-0339-8
Pfaller M. A., Diekema D. J., Gibbs D. L., Newell V. A., Ellis D., Tullio V., Rodloff A., Fu W., Ling T. A., , Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion, 10.1128/jcm.02117-09
Arendrup M.C., Update on antifungal resistance in Aspergillus and Candida, 10.1111/1469-0691.12513
Pfaller M. A., Messer S. A., Woosley L. N., Jones R. N., Castanheira M., Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance, 10.1128/jcm.00308-13
Arendrup Maiken C., Perlin David S., Echinocandin resistance : an emerging clinical problem?, 10.1097/qco.0000000000000111
Farmakiotis Dimitrios, Tarrand Jeffrey J., Kontoyiannis Dimitrios P., Drug-ResistantCandida glabrataInfection in Cancer Patients, 10.3201/eid2011.140685
Alexander Barbara D., Johnson Melissa D., Pfeiffer Christopher D., Jiménez-Ortigosa Cristina, Catania Jelena, Booker Rachel, Castanheira Mariana, Messer Shawn A., Perlin David S., Pfaller Michael A., Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations, 10.1093/cid/cit136
Vallabhaneni Snigdha, Cleveland Angela A., Farley Monica M., Harrison Lee H., Schaffner William, Beldavs Zintar G., Derado Gordana, Pham Cau D., Lockhart Shawn R., Smith Rachel M., Epidemiology and Risk Factors for Echinocandin NonsusceptibleCandida glabrataBloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008–2014, 10.1093/ofid/ofv163
Pfaller M. A., Castanheira M., Lockhart S. R., Ahlquist A. M., Messer S. A., Jones R. N., Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata, 10.1128/jcm.06112-11
Cornely O.A., Bassetti M., Calandra T., Garbino J., Kullberg B.J., Lortholary O., Meersseman W., Akova M., Arendrup M.C., Arikan-Akdagli S., Bille J., Castagnola E., Cuenca-Estrella M., Donnelly J.P., Groll A.H., Herbrecht R., Hope W.W., Jensen H.E., Lass-Florl C., Petrikkos G., Richardson M.D., Roilides E., Verweij P.E., Viscoli C., Ullmann A.J., ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients, 10.1111/1469-0691.12039
van der Geest Patrick J., Rijnders Bart J. A., Vonk Alieke G., Groeneveld A. B. Johan, Echinocandin to fluconazole step-down therapy in critically ill patients with invasive, susceptibleCandida albicansinfections, 10.1111/myc.12450
Pryce T. M., Palladino S., Kay I. D., Coombs G. W., Rapid identification of fungi by sequencing the ITS1 and ITS2 regions using an automated capillary electrophoresis system, 10.1080/13693780310001600435
European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antifungal Agents. Breakpoint tables for interpretation of MICs. Version 7.0, valid from 2014-08-12
Cleveland Angela Ahlquist, Harrison Lee H., Farley Monica M., Hollick Rosemary, Stein Betsy, Chiller Tom M., Lockhart Shawn R., Park Benjamin J., Declining Incidence of Candidemia and the Shifting Epidemiology of Candida Resistance in Two US Metropolitan Areas, 2008–2013: Results from Population-Based Surveillance, 10.1371/journal.pone.0120452
Lockhart S. R., Iqbal N., Cleveland A. A., Farley M. M., Harrison L. H., Bolden C. B., Baughman W., Stein B., Hollick R., Park B. J., Chiller T., Species Identification and Antifungal Susceptibility Testing of Candida Bloodstream Isolates from Population-Based Surveillance Studies in Two U.S. Cities from 2008 to 2011, 10.1128/jcm.01283-12
Pfaller Michael A, Messer Shawn A, Jones Ronald N, Castanheira Mariana, Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010–2012), 10.1038/ja.2015.29
Marcos-Zambrano L. J., Escribano P., Sanchez C., Munoz P., Bouza E., Guinea J., Antifungal Resistance to Fluconazole and Echinocandins Is Not Emerging in Yeast Isolates Causing Fungemia in a Spanish Tertiary Care Center, 10.1128/aac.02670-14
Huang L., Zhang Y. Y., Sun L. Y., Time to positivity of blood culture can predict different Candida species instead of pathogen concentration in candidemia, 10.1007/s10096-013-1826-8
Horvath L. L., George B. J., Murray C. K., Harrison L. S., Hospenthal D. R., Direct Comparison of the BACTEC 9240 and BacT/ALERT 3D Automated Blood Culture Systems for Candida Growth Detection, 10.1128/jcm.42.1.115-118.2004
Dixon P., Davies P., Hollingworth W., Stoddart M., MacGowan A., A systematic review of matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry compared to routine microbiological methods for the time taken to identify microbial organisms from positive blood cultures, 10.1007/s10096-015-2322-0
Bibliographic reference
Trouvé, C. ; Blot, Stijn ; Hayette, Marie-Pierre ; Jonckheere, Stijn ; Patteet, Sofie ; et. al. Epidemiology and reporting of candidaemia in Belgium: a multi-centre study. In: European Journal of Clinical Microbiology & Infectious Diseases, Vol. 36, no. 4, p. 649-655 (2017)
Lagrou, Katrien
